Cryptoinvestments begin with us
metarating
A1
ICOinspect
  • A1: Highest public scores and ratings. Generally that means that ICO has lowest risks. Such ICOs should be definitely paid closest attention to.
hypescale
+0.0K
24h followers growth
56.6K
total followers
Facebook
-
0.0
Twitter
+0K
14.9K
Telegram
-0.1K
36.1K
Bitcointalk
+0.1K
5.6K
Start: TBA
End: TBA
Estonia
metarating
A3
ICOinspect
  • A3: High public scores and ratings, but not as good as A1 or A2. Generally low risks. Such ICOs should be definitely paid closest attention to.
hypescale
+0.0K
24h followers growth
45.6K
total followers
Facebook
-
0.0
Twitter
+0.1K
13.1K
Telegram
+0K
32.5K
Bitcointalk
-
0.0
Start: TBA
End: TBA
USA
metarating
A2
ICOinspect
  • A2: “A2” rating denotes expectations of very low investment risk. “A2” indicates very strong capacity for ICO and project success. This capacity is not significantly vulnerable to foreseeable events.
hypescale
+0.0K
24h followers growth
130.1K
total followers
Facebook
-
0.0
Twitter
+0K
26.4K
Telegram
-0.1K
94.6K
Bitcointalk
+0.1K
9.1K
Start: 2018-09-01
End: 2018-09-30
Singapore
metarating
-
ICOinspect
  • -: Not available yet. Coming soon.
hypescale
+0.0K
24h followers growth
92.8K
total followers
Facebook
-
0.0
Twitter
+0K
20.6K
Telegram
+0K
22.7K
Bitcointalk
+0K
49.5K
Start: 2018-06-18
End: 2018-12-31
Estonia
metarating
-
ICOinspect
  • -: Not available yet. Coming soon.
hypescale
+0.0K
24h followers growth
0.8K
total followers
Facebook
-
0.0
Twitter
+0K
0.7K
Telegram
-
0.0
Bitcointalk
-
0.1
Start: 2018-08-16
End: 2018-12-14
Belize
metarating
-
ICOinspect
  • -: Not available yet. Coming soon.
hypescale
+0.0K
24h followers growth
0.7K
total followers
Facebook
-
0.0
Twitter
-
0.0
Telegram
+0K
0.1K
Bitcointalk
-
0.6
Start: 2018-06-09
End: 2018-09-30
United Kingdom
metarating
-
ICOinspect
  • -: Not available yet. Coming soon.
hypescale
+0.0K
24h followers growth
72.2K
total followers
Facebook
-
0.0
Twitter
+0K
18.1K
Telegram
+0K
53.2K
Bitcointalk
+0.1K
0.9K
Start: 2018-09-10
End: 2018-11-07
Singapore
metarating
A3
ICOinspect
  • A3: “A3” rating denotes expectations of low investment risk. The project capacity is considered strong. This capacity may, nevertheless, be more vulnerable to adverse business or economic conditions than is the case for higher ratings.
hypescale
+0.0K
24h followers growth
2.5K
total followers
Facebook
-
0.0
Twitter
+0K
2.5K
Telegram
-
0.0
Bitcointalk
-
0.0
Start: TBA
End: TBA
United Kingdom
metarating
A3
ICOinspect
  • A3: “A3” rating denotes expectations of low investment risk. The project capacity is considered strong. This capacity may, nevertheless, be more vulnerable to adverse business or economic conditions than is the case for higher ratings.
hypescale
+8.2K
24h followers growth
133.5K
total followers
Facebook
-
0.0
Twitter
+0.9K
20.2K
Telegram
+7.1K
98.1K
Bitcointalk
+0.2K
15.2K
Start: 2018-07-04
End: 2018-10-31
United Kingdom
metarating
A3
ICOinspect
  • A3: “A3” rating denotes expectations of low investment risk. The project capacity is considered strong. This capacity may, nevertheless, be more vulnerable to adverse business or economic conditions than is the case for higher ratings.
hypescale
+0.0K
24h followers growth
8.4K
total followers
Facebook
-
0.0
Twitter
+0K
8.4K
Telegram
+0K
0.0K
Bitcointalk
-
0.0
Start: 2018-10-01
End: 2018-12-30
USA

Shivom (OMX)

metarating
A3
  • A3: High public scores and ratings, but not as good as A1 or A2. Generally low risks. Such ICOs should be definitely paid closest attention to.
hypescale
-0.2K
24h followers growth
88.2K
total followers
Facebook
+0.0K
24h followers growth
0.0K
total followers
Twitter
+0.0K
24h followers growth
44.2K
total followers
Telegram
+-0.1K
24h followers growth
44K
total followers
Bitcointalk
+0.0K
24h views growth
0.0K
total views
* There are two digit in hypescale widget. First is 24h followers growth. Second is total followers.
install widget
Loading ICOs

Shivom is powering the next era of genomics through blockchain technology – by protecting identity, personalizing healthcare, transforming lives. Our blockchain based genomics and healthcare platform will allow the transition to value-based precision healthcare. Our focus is on the transformational convergence of OMICS technologies with blockchain, artificial intelligence and machine learning to enable secure and personalized medicine with global scalability.
We envision a future where genomic data becomes ubiquitous, with its insights for enhancing healthcare securely available and accessible to all. Shivom is pioneering the omics ecosystem to make this vision a reality by offering a first-of-its-kind investment proposition in the rapidly growing market for personalized medicine, powered by state-of-the-art blockchain technology.
We will additionally build a state-of-the art and not-for-profit drug discovery and precision medicine organization. Shivom researchers will use data-driven tools and techniques, particularly machine learning methods that underpin artificial intelligence, which will offer promise in improving healthcare systems and services around the globe.
Blockchain technology is our tech partner of choice because it is able to address trust issues, including patient consent, data ownership, data integrity, and authentication.
Blockchain can also manage complex data rights and allow finegrained access using smart contracts.

 

Executive Summary

Start: 2018-04-16 00:00:00
End: 2018-05-16 23:59:59
Token
OMX
Token price
TBA
Minimum investment
Accepting
Bonus
TBA
Overall token supply
3,000,000,000
Sale on ico
990,000,000
Platform
Ethereum
Milestones
  • 1
    2017 - 2018

    conceptualization healthcare ecosystem initiated | start of global roadshow | seed round of $250k finished | whitepaper released

  • 2
    April 2018

    OmiX token sale starts

  • 3
    Q1-Q2 2018

    Shivom foundation established | partnership major crypto vc

  • 4
    Q2 2018

    pharma partner on board | platform alpha release | project gaia started

  • 5
    Q2/Q3 2018

    web marketplace open

  • 6
    Q3/Q4 2018

    formation R&D unit. Official start of global not-forprofit pharmaceutical spin-of

  • 7
    Q4 2018

    first genomics service unit opens. First genomics counseling service unit opens | first rare- disease subset

  • 8
    Q3/Q4 2018

    worldwide rollout of Shivom platform. Shivom services are available on a global scale on all continents

  • 9
    Q4 2018/Q1 2019

    multi-omics integration

  • 10
    Q4 2018/ Q1 2019

    A.I. platform. Implementation of artificial intelligence, deep learning platform

Team
CO-FOUNDER & CEO

DR. AXEL SCHUMACHER
CO-FOUNDER & COO

GOURISH SINGLA
CO-FOUNDER & CMO

SALLY EAVES
CO-FOUNDER & CSO

PER LIND
CHIEF INNOVATION OFFICER

HENRY INES
CO-FOUNDER & CTO

AKASH GAURAV
CO-FOUNDER & CHIEF TECHNOLOGY ADVISOR

KUMAR GAURAV
CHIEF SCIENTIFIC OFFICER

DR. NATALIE PANKOVA
VP MARKETING

AGAM KANSAL
INVESTMENT LEAD

CHARLES LESLIE
HEAD - SEARCH & DIGITAL MARKETING

AJIT SINGH KULAR
MIDDLE EAST HEAD

DR. RASHAD IBRAHIM
CHINESE SUBCONTINENT HEAD

STEPHANE LAURENT
HEAD OF PUBLIC RELATIONS

AZAM SHAGHAGHI
PUBLIC RELATIONS MANAGER

TING PENG
DESIGN LEAD

KAYLEEN SCHREIBER
INVESTMENT LEAD

PIERRE MAAREK
Advisors
Sorry, the ICO does not specify the advisors

Leave a comment

Your email address will not be published. Required fields are marked *

Hide more info
Dear ICOinspect.com user! Help us to become better by taking part in the survey.
Hello. Add your message here.